 |
|
|
| |
Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Dolutegravir + Rilpivirine: Results From the SWORD-1 and SWORD-2 Studies
|
| |
| |
Reported by Jules Levin
16th European AIDS Conference; October 25-27, 2017; Milan, Italy
Alan Oglesby,1Yogesh Punekar,2Kostas Angelis,3Antonio Antela,4Michael Aboud,2Elizabeth Blair,1Lesley Kahl,2Martin Gartland,1Brian Wynne,5Miranda Murray2
1ViiV Healthcare, Research Triangle Park, NC, USA; 2ViiV Healthcare, Brentford, UK; 3GlaxoSmithKline, Uxbridge, UK; 4Infectious Diseases Unit, Hospital Clinico de Santiago, La Coruna, Spain; 5ViiV Healthcare, Collegeville, PA, USA
|
| |
|
|
|
|
|
